Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07062198Phase 3Recruiting

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Role: lead

NCT04573153Phase 2Terminated

Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients

Role: lead

NCT04330326Phase 2Completed

Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease

Role: lead

NCT04044131Phase 2Completed

Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients

Role: collaborator

All 4 trials loaded